Loading
companiesCompany
Anbogen Therapeutics
Anbogen Therapeutics is a Taiwan-based biotechnology company that leads 2 cancer trials in OnCo, testing ABT-101 and ABT-301 in colorectal cancer and non-small-cell lung cancer.
Also called: 安邦生技
Overview
Anbogen Therapeutics is a precision oncology company in Taipei developing targeted cancer therapies. Its candidates include ABT-101, licensed from Taiwan's National Health Research Institutes, and ABT-301, licensed from Taipei Medical University. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT07244705 (phase 1/2, A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advance...) and NCT05532696 (phase 1/2, Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Taipei, TW
Scorecard
All companies#57of 1244 companies, score 67
- approved products +12
- phase 1/2 +1
- targets +6
- modalities +4
- regions +8
- 24-month regulatory events +6
- registry trials +30
2 approved, 0 in phase 3, 1 earlier, 3 targets, 3,051 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2019
Phase 2small molecule
ABT-301 is an experimental small-molecule drug from Anbogen Therapeutics in phase 2 trials for colorectal cancer, aimed at Histone deacetylases (HDAC).
ApprovedMonoclonal antibody (anti-PD-1)
Tislelizumab · Tevimbra
A Chinese-developed PD-1 blocker, engineered to avoid a side-channel that may blunt other PD-1 drugs, now approved in the US and EU for oesophageal and stomach cancer.
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
Similar pages
- TrialStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Shares Tislelizumab, Colorectal cancer, Non-small-cell lung cancer.
- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
Shares Tislelizumab, Bevacizumab, Non-small-cell lung cancer.
- TrialA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
Shares Tislelizumab, Colorectal cancer.
- TrialTislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis
Shares Tislelizumab, Bevacizumab.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Tislelizumab, Non-small-cell lung cancer.
- TrialStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Tislelizumab, Colorectal cancer, Non-small-cell lung cancer.
- PersonJie Wang
Shares Tislelizumab, Non-small-cell lung cancer.
- TrialAddition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
Shares Tislelizumab, Non-small-cell lung cancer.
cancers
drugs
Phase 2small molecule
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedMonoclonal antibody (anti-PD-1)
Tislelizumab · Tevimbra